Home
Conditions
Lymphoproliferative Disorders

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,146 public trials 2,034 recruiting studies

Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Recruiting

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

NCT07509086

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations: The First Hospital of Jilin University Changchun, Jilin, China

View Trial Details

Recruiting

ATRA and Carfilzomib in Plasma Cell Myeloma Patients

NCT06536413

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Houston Methodist Neal Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

NCT05544968

Conditions: CD30+ Anaplastic Large Cell Lymphoma, CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma, CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma, +19 more
Locations: Froedtert & the Medical College of Wisconsin Milwaukee, Wisconsin, United States

View Trial Details

Recruiting

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

NCT03587844

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations: Stanford University Medical Center Stanford, California, United States

Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen Montvale, New Jersey, United States

View Trial Details

Recruiting

Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma

NCT06252792

Conditions: Blood Protein Disorders, Cardiovascular Diseases, First Relapse, +13 more
Locations: The First Hospital of Jilin University Changchun, Jilin, China

View Trial Details

Recruiting

R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

NCT05257018

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Dongmei Ji Shanghai, Shanghai Municipality, China

Cancer Hospital affilicaited to Xinjiang Medical University Ürümqi, Xinjiang, China

View Trial Details

Recruiting

Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma

NCT04512534

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Dongmei Ji Shanghai, Shanghai Municipality, China

View Trial Details

Recruiting

Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma

NCT07508605

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: Shenzhen University General Hospital Shenzhen, Guangdong, China

View Trial Details

Recruiting

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

NCT06451497

Conditions: Biliary Tract Cancer, Biliary Tract Diseases, Biliary Tract Neoplasms, +58 more
Locations: Dana Farber Cancer Institute Boston, Massachusetts, United States

NEXT Oncology Austin, TX 78758, Texas, United States

NEXT Oncology San Antonio, Texas, United States

View Trial Details

Recruiting

Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

NCT07047885

Conditions: Cutaneous T Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Moffitt Cancer Center Tampa, Florida, United States

View Trial Details

Lymphoproliferative Disorders

Lymphoproliferative Disorders trial results

Related conditions